Drug intelligence / Profile preview

ambrosia elatior allergen extract

Development stage
Phase 2
Lead developer
Leti Pharma
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Percutaneous
01

Overview

Ambrosia elatior allergen extract is a native biological allergen extract derived from the pollen of common ragweed (*Ambrosia elatior*), developed by LETI Pharma. It contains a mixture of ragweed pollen proteins, including major allergens such as Amb a 1, which possess IgE-binding capacity. The extract is primarily used for the diagnosis and treatment of IgE-mediated allergic conditions, such as allergic rhinitis, allergic conjunctivitis, and allergic asthma. In clinical development, it has been investigated in Phase 2 biological standardization studies to determine the concentration required to induce a skin prick test wheal size equivalent to 10 mg/ml histamine hydrochloride, ensuring diagnostic accuracy and safety in sensitized patients.

Other names
Ambrosia elatior pollen allergen extractCommon ragweed allergen extractnative Ambrosia elatior allergen extract
02

Targets

BCR (Immunoglobulin G B Cell Receptor)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)CD4+ T cells specific for Ambrosia elatior allergen-derived peptides

Beyond the preview

Go deeper on ambrosia elatior allergen extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ambrosia elatior allergen extract.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call